Submission includes results of the pivotal DISSOLVE I and II studies NASP PDUFA date set for 27 June 2026 STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, today...
Hence then, the article about fda accepts biologics license application for sobi s nasp for patients with uncontrolled gout was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout )
Also on site :
- Witney Carson Claps Back at ‘DWTS’ Judge Carrie Ann Inaba, Joining Uproar Over Comments on Guillermo Rodriguez: ‘I Said What I Said’
- ‘The Debut’: Jesse Eisenberg Praises Oscar Frontrunner Julianne Moore’s ‘Perfect Performance’ at NYFF
- James Gunn Responds to ‘Clayface’ Criticism: ‘The Public Voting on What IP They Want to See’ Isn’t ‘the Only Way to Make a Movie’